A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

NCT01845987 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Palmoplantaris Pustulosis

Interventions

DRUG: Placebo
DRUG: CNTO 1959

Sponsor

Janssen Pharmaceutical K.K.